RecruitingNCT03615235

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Sponsor

Wake Forest University Health Sciences

Enrollment

5,000 participants

Start Date

Mar 21, 2019

Study Type

OBSERVATIONAL

Conditions

Kidney Disease, Chronic Kidney Diseases Kidney Failure

Summary

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study (called APOLLO) is tracking the long-term kidney health of transplant donors and recipients who have African ancestry, to understand how a specific gene variant (called APOL1) affects kidney transplant outcomes over time. **You may be eligible if...** - You are an adult living kidney donor with recent African ancestry (including African American, Afro-Caribbean, Hispanic Black, or African) - You are willing and able to provide informed consent **You may NOT be eligible if...** - You are unable or unwilling to provide informed consent - Note: Recruitment of deceased donors and transplant recipients has ended — only living donors are currently being enrolled Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(18)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of California San Francisco

San Francisco, California, United States

University of Miami / Miami Transplant Institute

Miami, Florida, United States

Emory University School of Medicine

Atlanta, Georgia, United States

University of Maryland School of Medicine

Baltimore, Maryland, United States

Johns Hopkins University

Baltimore, Maryland, United States

Joslin Diabetes Center / Harvard University

Boston, Massachusetts, United States

University of Michigan Medicine

Ann Arbor, Michigan, United States

Saint Louis University Center for Transplantation

St Louis, Missouri, United States

Ichan School of Medicine at Mount Sinai

New York, New York, United States

Columbia University Irving Medical Center

New York, New York, United States

Weill Cornell Medicine

New York, New York, United States

Duke University

Durham, North Carolina, United States

Wake Forest School of Medicine

Winston-Salem, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

University of Wisconsin - Madison

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03615235

Related Trials

Supporting VETerans With Kidney Disease Through Food As Medicine

NCT071947331 location

Proteomic Analysis of Amniotic Fluid to Predict Postnatal Renal Function in Fetuses With Renal and Urinary Tract Malformations

NCT069124901 location

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824452 locations

NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities

NCT068106222 locations

Testosterone Treatment in Men With Chronic Kidney Disease

NCT052496341 location